24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Pharmaceuricals
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:58
Intel VP: "Historically, if we were to miss milestones... we usually just gave exemptions. Saying no is a pretty powerful tool"
13:35
“We’re already living in a world where AI is attacking AI”
13:33
“In many cases the first market should not be America”
13:31
“To get Israel to a more precise position in biotech, we need to educate our people to become better managers”
More stories
Buzz
Most popular
Daily
Weekly
1
“Other countries have air-defense systems, but Israel’s are better”: Arrow 3 lands in Germany as Israel pursues new mega deals
2
Johny Srouji weighs leaving Apple, raising stakes for the Israeli executive who built its silicon program
3
Nice puts Actimize up for sale at a $1.5-2 billion price tag
4
Israeli drone startup Heven hits $1 billion valuation in $100 million round led by IonQ
5
Check Point raises $1.75 billion, potentially eyeing AI expansion
More news
Pharmaceuricals
3 stories about Pharmaceuricals
Closure of another criminal case will help Teva's new CEO to focus on return to growth
22.08.23
|
Sophie Shulman
The pharmaceutical company has reached a compromise after being suspected of price-fixing with other generic drug manufacturers in the US. In the first four years, it will pay $22.5 million and in 2028 - $135 million. In addition, the company will donate two drugs worth $50 million to humanitarian organizations
Schultz kept Teva away from the abyss, but couldn't find a runway to growth
22.11.22
|
Sophie Shulman
Kare Schultz, who served as CEO of the pharmaceutical company for the past five years, has left the company a year early after amassing a salary of more than $100 million. His replacement, Richard Francis, is taking over with less debt and less legal issues, but with the big challenge of creating new growth engines
United Therapeutics to Acquire Pharma Company SteadyMed in a $216 Deal
30.04.18
|
Amarelle Wenkert
In 2017, Israeli-founded SteadyMed won a patent war against United Therapeutics